Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATSN-201 gene therapy for RS1-associated X-linked retinoschisis
NL-OMON61668Phase 3Not yet recruiting
- Sponsor
- Atsena Therapeutics
- Start
- Oct 2026
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ATSN-201 in X-linked retinoschisis (XLRS) and Fundus dystrophy, sponsored by Atsena Therapeutics. Primary endpoint: Change from baseline in microperimetry across prespecified loci in the study eye. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ATSN-201
03
Conditions
X-linked retinoschisis (XLRS)Fundus dystrophy
Beyond the preview
Go deeper on NL-OMON61668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61668.